...
首页> 外文期刊>The journal of clinical investigation >Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
【24h】

Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance

机译:儿童急性淋巴细胞白血病细胞需要诱导自噬依赖性坏死病克服糖皮质激素抵抗

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In vivo resistance to first-line chemotherapy, including to glucocorticoids, is a strong predictor of poor outcome in children with acute lymphoblastic leukemia (ALL). Modulation of cell death regulators represents an attractive strategy for subverting such drug resistance. Here we report complete resensitization of multidrug-resistant childhood ALL cells to glucocorticoids and other cytotoxic agents with subcytotoxic concentrations of obatoclax, a putative antagonist of BCL-2 family members. The reversal of glucocorticoid resistance occurred through rapid activation of autophagy-dependent necroptosis, which bypassed the block in mitochondrial apoptosis. This effect was associated with dissociation of the autophagy inducer beclin-1 from the antiapoptotic BCL-2 family member myeloid cell leukemia sequence 1 (MCL-1) and with a marked decrease in mammalian target of rapamycin (mTOR) activity. Consistent with a protective role for mTOR in glucocorticoid resistance in childhood ALL, combination of rapamycin with the glucocorticoid dexamethasone triggered autophagy-dependent cell death, with characteristic features of necroptosis. Execution of cell death, but not induction of autophagy, was strictly dependent on expression of receptor-interacting protein (RIP-1) kinase and cylindromatosis (turban tumor syndrome) (CYLD), two key regulators of necroptosis. Accordingly, both inhibition of RIP-1 and interference with CYLD restored glucocorticoid resistance completely. Together with evidence for a chemosensitizing activity of obatoclax in vivo, our data provide a compelling rationale for clinical translation of this pharmacological approach into treatments for patients with refractory ALL.
机译:一线化疗(包括糖皮质激素)的体内抗药性是急性淋巴细胞白血病(ALL)患儿预后不良的有力预测指标。细胞死亡调节剂的调节代表了一种颠覆这种耐药性的有吸引力的策略。在这里,我们报告了亚药浓度的obatoclax(BCL-2家族假定的拮抗剂)的亚细胞毒性浓度,对耐多药的儿童ALL细胞对糖皮质激素和其他细胞毒性药物的完全重新敏感性。糖皮质激素抵抗的逆转通过自噬依赖性坏死病的快速激活而发生,其绕过了线粒体凋亡的阻滞。这种作用与自噬诱导因子beclin-1与抗凋亡BCL-2家族成员髓样细胞白血病序列1(MCL-1)的解离有关,并且与雷帕霉素(mTOR)活性的哺乳动物靶标显着降低有关。与mTOR在儿童ALL糖皮质激素抵抗中的保护作用一致,雷帕霉素与糖皮质激素地塞米松的组合可触发自噬依赖性细胞死亡,具有坏死性病的特征。细胞死亡的执行,而不是自噬的诱导,完全取决于受体相互作用蛋白(RIP-1)激酶和肾小管瘤病(头巾肿瘤综合征)(CYLD)的表达,这是坏死病的两个关键调节因子。因此,对RIP-1的抑制和对CYLD的干扰都完全恢复了糖皮质激素抵抗。连同奥巴托克在体内的化学增敏活性的证据,我们的数据为将该药理学方法临床转化为难治性ALL患者的治疗提供了令人信服的理由。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号